Tom Vanden Berghe is associate professor at the University of Antwerp and guest professor at the Ghent University. He performs translational cell death research. As a PI, he is increasingly recognised in the ferroptosis and inflammation research community. His multi-faceted ferroptosis platform (covering novel lead ferroptosis inhibitors, ferroptosis diagnostics, as well as ferroptosis nanomedicine anti-cancer therapeutics) is under negotiation with investigators in preparation of a spin-off case (launch planned Q3 2024). He published 122 pubmed-indexed peer-reviewed papers, cited >32000 times with an H-index of 62. More details @ https://www.vanden-berghe-lab.com/.